- $8.48bn
- $8.17bn
- $2.26bn
- 100
- 21
- 62
- 64
Annual cashflow statement for Chemed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 220 | 319 | 269 | 250 | 273 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 29.9 | 29.8 | 22.3 | 38 | 43.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 8.98 | 45.7 | -25.5 | -33.5 | -38.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 301 | 489 | 309 | 310 | 330 |
| Capital Expenditures | -53 | -58.8 | -58.7 | -57.3 | -56.9 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -138 | -2.73 | 0.918 | -2.08 | -3.79 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -191 | -61.6 | -57.8 | -59.4 | -60.6 |
| Financing Cash Flow Items | -28 | -25.1 | -15.3 | -18.3 | -9.07 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -109 | -271 | -381 | -209 | -79.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.33 | 157 | -130 | 41.2 | 190 |